Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the Company and CTS Ltd. (“CTS”) have agreed to collaborate on product development.
CTS is a leading pharmaceutical and consumer products company in Israel. Founded in 1921, CTS focuses on solutions that have clinically proven efficacy and safety, supporting the health of people. In addition, CTS imports, registers, markets, and distributes healthcare products of leading global pharmaceutical companies across Israel.
As part of the collaboration, Clearmind Medicine will have access to the CTS’ state-of-the-art facilities, allowing it to expand its research and development capabilities. Furthermore, the collaboration provides Clearmind access to CTS’ global networks and industry connections, the ability to leverage CTS’ expertise in manufacturing and marketing, as well as benefit from CTS’ vast industry experience and guidance, ensuring that the Company’s treatments meet the highest standards of quality, safety, and efficacy.
“We are honored to collaborate with such a prominent pharmaceutical company. CTS’ support and expertise will be invaluable as we advance our research and development efforts in psychedelic-based therapeutics. This significant milestone recognizes Clearmind Medicine’s innovative approach as well as highlights the growing interest in the field of psychedelic-based therapies within the pharmaceutical industry. Together, we have the opportunity to revolutionize mental health treatments and provide much-needed relief to individuals suffering from a range of mental health conditions,”
Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of fourteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.